The estimated Net Worth of V Bryan Lawlis is at least 6.14 百万$ dollars as of 15 May 2024. V Lawlis owns over 35,000 units of Biomarin Pharmaceutical stock worth over 2,967,300$ and over the last 17 years he sold BMRN stock worth over 2,712,732$. In addition, he makes 458,270$ as Independent Director at Biomarin Pharmaceutical.
V has made over 30 trades of the Biomarin Pharmaceutical stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 35,000 units of BMRN stock worth 67,900$ on 15 May 2024.
The largest trade he's ever made was exercising 35,000 units of Biomarin Pharmaceutical stock on 15 May 2024 worth over 67,900$. On average, V trades about 2,593 units every 56 days since 2007. As of 15 May 2024 he still owns at least 35,000 units of Biomarin Pharmaceutical stock.
You can see the complete history of V Lawlis stock trades at the bottom of the page.
Dr. V. Bryan Lawlis, Jr., Ph.D., is an Independent Director of Biomarin Pharmaceutical Inc. Dr. Lawlis joined our Board in June 2007. From August 2011 to September 2017 he served as the President and Chief Executive Officer of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc., a private biotechnology company. Dr. Lawlis co-founded and served as President and Chief Executive Officer of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011. Dr. Lawlis served as President and Chief Executive Officer of Aradigm Corporation, a pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and Chief Executive Officer from 1996 to 1999, and as its Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. From 1981 to 1996, Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. His last position at Genentech, Inc. was Vice President of Process Sciences. Dr. Lawlis serves on the boards of four other public biopharmaceutical companies: Geron Corporation since March 2012, Coherus Biosciences, Inc. since October 2014, Aeglea BioTherapeutics, Inc. since July 2018 and at Sutro Biopharma, Inc. since it went public in September 2018. He previously served on the board of KaloBios Pharmaceuticals, Inc., a public biopharmaceutical company, from August 2013 until September 2014, and acted as the Chairman of the scientific advisory board for Coherus from November 2012 to June 2016. .
As the Independent Director of Biomarin Pharmaceutical, the total compensation of V Lawlis at Biomarin Pharmaceutical is 458,270$. There are 14 executives at Biomarin Pharmaceutical getting paid more, with Jean-Jacques Bienaime having the highest compensation of 18,405,900$.
V Lawlis is 68, he's been the Independent Director of Biomarin Pharmaceutical since 2007. There are 3 older and 18 younger executives at Biomarin Pharmaceutical. The oldest executive at Biomarin Pharmaceutical Inc. is Alan Lewis, 74, who is the Independent Director.
V's mailing address filed with the SEC is C/O GERON CORPORATION, 919 E. HILLSDALE BLVD, SUITE 250, FOSTER CITY, CA, 94404.
Over the last 21 years, insiders at Biomarin Pharmaceutical have traded over 153,109,113$ worth of Biomarin Pharmaceutical stock and bought 151,118 units worth 2,557,509$ . The most active insiders traders include Jean Jacques Bienaime、Mark J Enyedy、Kathryn E Falberg. On average, Biomarin Pharmaceutical executives and independent directors trade stock every 8 days with the average trade being worth of 912,996$. The most recent stock trade was executed by Erin Burkhart on 13 August 2024, trading 714 units of BMRN stock currently worth 64,260$.
biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment
Biomarin Pharmaceutical executives and other stock owners filed with the SEC include: